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Abstract
BACKGROUND—The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, 
when added to standard care in patients with type 2 diabetes, remains unknown.
METHODS—In this double-blind trial, we randomly assigned patients with type 2 diabetes and 
high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the 
time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be 
noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper 
boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were 
performed for the prespecified exploratory outcomes.
RESULTS—A total of 9340 patients underwent randomization. The median follow-up was 3.8 
years. The primary outcome occurred in significantly fewer patients in the liraglutide group (608 
of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 
95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority). 
Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than 
in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P=0.007). The rate of 
death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo 
group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P =0.02). The rates of nonfatal 
myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly 
lower in the liraglutide group than in the placebo group. The most common adverse events leading 
to the discontinuation of liraglutide were gastrointestinal events. The incidence of pancreatitis was 
nonsignificantly lower in the liraglutide group than in the placebo group.
CONCLUSIONS—In the time-to-event analysis, the rate of the first occurrence of death from 
cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 
2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and 
the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.)
Type 2 diabetes is a complex metabolic disorder that is characterized by hyperglycemia and 
associated with a high risk of cardiovascular, microvascular, and other complications.1,2 
Although glycemic control is associated with reductions in the risk of microvascular 
complications, the macrovascular benefits of glycemic control are less certain. Furthermore, 
concern has been raised about the cardiovascular safety of antihyperglycemic therapies.3 
Consequently, regulatory authorities have mandated cardiovascular safety assessments of 
new diabetes treatments.4,5
Liraglutide, an analogue of human glucagon-like peptide 1 (GLP-1),6 has been approved for 
the treatment of type 2 diabetes. Its efficacy in lowering glucose levels has been established, 
and it has been associated with slight reductions in weight and blood pressure.6–8 It has been 
associated with an increase in pulse rate.7,8 To assess the long-term effects of liraglutide on 
cardiovascular outcomes and other clinically important events, the Liraglutide Effect and 
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Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial was 
initiated in 2010.9
METHODS
TRIAL DESIGN AND OVERSIGHT
We performed this multicenter, double-blind, placebo-controlled trial at 410 sites in 32 
countries. Detailed methods of the trial have been published previously,9 and the trial 
protocol is available with the full text of this article at NEJM.org. The trial protocol was 
reviewed and approved by the institutional review board or ethics committee at each 
participating center. All the patients provided written informed consent before participation. 
Patients with type 2 diabetes who were at high risk for cardiovascular disease were 
randomly assigned, in a 1:1 ratio, to receive liraglutide or placebo. The minimum planned 
follow-up was 42 months, with a maximum of 60 months of receiving the assigned regimen 
and an additional 30 days of follow-up afterward.
The trial was overseen by a steering committee consisting of 11 academic investigators and 
4 employees of the sponsor. The steering committee, in collaboration with the sponsor and 
regulatory authorities, was responsible for designing the trial protocol. An independent data 
and safety monitoring committee performed ongoing safety surveillance and had access to 
all the data in an unblinded fashion. The protocol for the treatment of risk factors and the 
concomitant use of medications was developed by a global expert panel (Table S1 in the 
Supplementary Appendix, available at NEJM.org). The data were gathered by the site 
investigators, and the sponsor performed site monitoring and data collection. The data were 
analyzed by Statogen Consulting and the sponsor.
All the authors had access to the final results and vouch for the fidelity of the trial to the 
protocol. The first and last authors wrote the first draft of the manuscript, which was revised 
and approved by all the authors, who also assume responsibility for the accuracy and 
completeness of its content and for the decision to submit the manuscript for publication. 
Editorial support, funded by the sponsor, was provided by an independent medical writer 
under the guidance of the authors.
PATIENTS
Patients with type 2 diabetes who had a glycated hemoglobin level of 7.0% or more were 
eligible if they either had not received drugs for this condition previously or had been treated 
with one or more oral antihyperglycemic agents or insulin (human neutral protamine 
Hagedorn, long-acting analogue, or premixed) or a combination of these agents. The major 
inclusion criteria were the following: an age of 50 years or more with at least one 
cardiovascular coexisting condition (coronary heart disease, cerebrovascular disease, 
peripheral vascular disease, chronic kidney disease of stage 3 or greater, or chronic heart 
failure of New York Heart Association class II or III) or an age of 60 years or more with at 
least one cardiovascular risk factor, as determined by the investigator (microalbuminuria or 
proteinuria, hypertension and left ventricular hypertrophy, left ventricular systolic or 
diastolic dysfunction, or an ankle–brachial index [the ratio of the systolic blood pressure at 
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the ankle to the systolic blood pressure in the arm] of less than 0.9).9 Major exclusion 
criteria were type 1 diabetes; the use of GLP-1–receptor agonists, dipeptidyl peptidase 4 
(DPP-4) inhibitors, pramlintide, or rapid-acting insulin; a familial or personal history of 
multiple endocrine neoplasia type 2 or medullary thyroid cancer; and the occurrence of an 
acute coronary or cerebrovascular event within 14 days before screening and randomization. 
The complete inclusion and exclusion criteria are listed in the Supplementary Appendix.
PROCEDURES
After a 2-week placebo run-in phase to establish whether patients were able to adhere to the 
injection regimen, patients were randomly assigned, in a 1:1 ratio, to receive either 1.8 mg 
(or the maximum tolerated dose) of liraglutide or matching placebo once daily as a 
subcutaneous injection in addition to standard care (Fig. S1 in the Supplementary 
Appendix). Randomization was stratified according to the estimated glomerular filtration 
rate (eGFR) at screening (<30 or ≥30 ml per minute per 1.73 m2 of body-surface area), as 
calculated with the use of the Modification of Diet in Renal Disease equation. For patients 
who did not meet the recommended target for glycemic control (glycated hemoglobin level 
≤7% or individualized target at the investigator’s discretion) after randomization, the 
addition of any antihyperglycemic agents except for GLP-1–receptor agonists, DPP-4 
inhibitors, or pramlintide was permitted. Patients were scheduled for follow-up visits at 
months 1, 3, and 6 and every 6 months thereafter.
OUTCOMES
The primary composite outcome in the time-to-event analysis was the first occurrence of 
death from cardiovascular causes, nonfatal (including silent) myocardial infarction, or 
nonfatal stroke. Prespecified exploratory outcomes included an expanded composite 
cardiovascular outcome (death from cardiovascular causes, nonfatal myocardial infarction, 
nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or 
heart failure), death from any cause, a composite renal and retinal microvascular outcome 
(nephropathy [defined as the new onset of macroalbuminuria or a doubling of the serum 
creatinine level and an eGFR of ≤45 ml per minute per 1.73 m2, the need for continuous 
renal-replacement therapy, or death from renal disease] and retinopathy [defined as the need 
for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or 
the onset of diabetes-related blindness]), neoplasms, and pancreatitis — all of which were 
adjudicated in a blinded fashion by an external, independent event-adjudication committee. 
The definitions that were used for the clinical events and the members of the committee are 
listed in the Supplementary Appendix.
The glycated hemoglobin level was measured at randomization, at month 3, and then every 6 
months thereafter. Other laboratory tests were performed at randomization, at months 6 and 
12, and annually thereafter. Prespecified comparisons between groups were performed at 36 
months, which was the last annual visit with laboratory testing that was prespecified for the 
entire trial population, given the minimum follow-up of 42 months.
Marso et al. Page 4
N Engl J Med. Author manuscript; available in PMC 2017 January 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
STATISTICAL ANALYSIS
The statistical analysis plan is available with the protocol at NEJM.org. We based the 
required sample size for the trial on an assumed annual primary-event rate of 1.8% in each 
group. Uniform enrollment was projected over the period of 1.5 years. Assuming a 
withdrawal rate of less than 10%, a minimum exposure to the trial regimen of 42 months, a 
null hypothesis hazard ratio of 1.30 or more, 90% power, and a one-sided alpha level of 
0.025, we calculated that 8754 patients would need to undergo randomization if we were to 
observe at least 611 primary outcomes.
The primary and exploratory analyses for the outcomes in the time-to-event analyses were 
based on a Cox proportional-hazards model with treatment as a covariate. The primary 
hypothesis was that liraglutide would be noninferior to placebo with regard to the primary 
outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the 
hazard ratio. We used a hierarchical testing strategy for the liraglutide group versus the 
placebo group, first testing for noninferiority and subsequently for superiority. 
Noninferiority was established for the primary outcome if the upper limit of the two-sided 
95% confidence interval of the hazard ratio was less than 1.30, and superiority was 
established if the upper limit was less than 1.00. In addition, prespecified sensitivity analyses 
were conducted (see the protocol). For exploratory outcomes, no adjustments of P values for 
multiplicity were performed. All the patients who underwent randomization were included 
in the primary and exploratory analyses, and data from the patients who completed or 
discontinued the trial without having an outcome were censored from the day of their last 
visit; events occurring after that visit were not included. Two-sided P values are presented 
throughout. We estimated the mean differences between the trial groups in the glycated 
hemoglobin level, weight, systolic and diastolic blood pressure, and pulse using a mixed 
model for repeated measurements, with adjustment for baseline covariates.
RESULTS
OVERVIEW OF TRIAL CONDUCT
A total of 9340 patients underwent randomization from September 2010 through April 2012; 
4668 patients were randomly assigned to receive liraglutide and 4672 to receive placebo. 
The planned closeout of follow-up of the patients was from August 2014 through December 
2015. The vital status was known in 99.7% of the patients. A total of 96.8% of the patients 
completed a final visit, died, or had a primary outcome. The median time of exposure to 
liraglutide or placebo was 3.5 years. The mean percentage of time that patients received the 
trial regimen was 84% for liraglutide and 83% for placebo. The median follow-up was 3.8 
years in each group. The median daily dose of liraglutide was 1.78 mg (interquartile range, 
1.54 to 1.79), including periods during which the patients did not receive liraglutide. The 
screening, randomization, and follow-up of the patients are shown in Figure S2 in the 
Supplementary Appendix.
The demographic and clinical characteristics of the patients were similar in the two groups 
(Table S2 in the Supplementary Appendix). Of the 9340 patients, the majority (7598 
[81.3%]) had established cardiovascular disease (6764 patients [72.4%]), chronic kidney 
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disease of stage 3 or higher (2307 [24.7%]), or both (1473 [15.8%]). At baseline, the mean 
duration of diabetes was 12.8 years, and the mean glycated hemoglobin level was 8.7%.
CARDIOVASCULAR OUTCOMES
The primary composite outcome occurred in fewer patients in the liraglutide group (608 of 
4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 
95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P = 0.01 for 
superiority) (Table 1 and Fig. 1A). Death from cardiovascular causes occurred in fewer 
patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) 
(hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P = 0.007) (Fig. 1B). The rate of death from any 
cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group 
(447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P = 0.02). The frequencies of 
nonfatal myocardial infarction and nonfatal stroke were lower in the liraglutide group than in 
the placebo group, although the differences were not significant (Fig. 1C and 1D and Table 
1). The magnitude of the differences was similar in sensitivity analyses with alternative 
censoring, including the per-protocol analysis (Fig. S3 in the Supplementary Appendix). 
Findings for the remaining adjudicated cardiovascular outcomes and the expanded 
composite outcome are provided in Table 1, and Figure S4 in the Supplementary Appendix.
Subgroup analyses are shown in Figure 2. Significant interactions were observed for an 
eGFR of 60 ml or more per minute per 1.73 m2 versus an eGFR of less than 60 ml per 
minute per 1.73 m2, with a benefit favoring the lower eGFR, and for the presence versus 
absence of established cardiovascular disease at baseline, with benefit for those with 
cardiovascular disease at baseline. Additional subgroup analyses regarding the eGFR are 
provided in Table S3 in the Supplementary Appendix.
GLYCEMIC CONTROL
Changes in the glycated hemoglobin values over time are shown in Figure S5A in the 
Supplementary Appendix. The prespecified analysis at 36 months showed a mean difference 
between the liraglutide group and the placebo group of −0.40 percentage points (95% CI, 
−0.45 to −0.34). Changes in the use of diabetes medication during the trial are shown in 
Table S4 in the Supplementary Appendix.
CARDIOVASCULAR RISK FACTORS
There were significant mean differences between the liraglutide group and the placebo group 
in the change from baseline to 36 months in the following variables: weight loss was 2.3 kg 
(95% CI, 2.5 to 2.0) higher in the liraglutide group, the systolic blood pressure was 1.2 mm 
Hg (95% CI, 1.9 to 0.5) lower in the liraglutide group, the diastolic blood pressure was 0.6 
mm Hg (95% CI, 0.2 to 1.0) higher in the liraglutide group, and the heart rate was 3.0 beats 
per minute (95% CI, 2.5 to 3.4) higher in the liraglutide group (Fig. S5B, S5C, and S5D in 
the Supplementary Appendix). The use of cardiovascular medications at baseline and during 
the trial is shown in Table S4 in the Supplementary Appendix.
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MICROVASCULAR OUTCOMES
The incidence of a composite outcome of renal or retinal microvascular events was lower in 
the liraglutide group than in the placebo group (hazard ratio, 0.84; 95% CI, 0.73 to 0.97; P = 
0.02), a difference that was driven by a lower rate of nephropathy events in the liraglutide 
group (1.5 vs. 1.9 events per 100 patient-years of observation; hazard ratio, 0.78; 95% CI, 
0.67 to 0.92; P = 0.003) (Table 1). The incidence of retinopathy events was nonsignificantly 
higher in the liraglutide group than in the placebo group (0.6 vs. 0.5 events per 100 patient-
years; hazard ratio, 1.15; 95% CI, 0.87 to 1.52; P = 0.33).
SAFETY AND ADVERSE EVENTS
Adverse events are listed in Table 2. The overall rates of benign or malignant neoplasms 
were higher in the liraglutide group than in the placebo group, but the difference was not 
significant (Fig. S6 in the Supplementary Appendix). There were 13 patients with pancreatic 
cancer in the liraglutide group and 5 in the placebo group. Additional data regarding 
pancreatic cancer are provided in Table S5 in the Supplementary Appendix. There were 
fewer patients with prostate cancer in the liraglutide group than in the placebo group (26 vs. 
47) and also fewer patients with leukemia (5 vs. 14) (Fig. S6 in the Supplementary 
Appendix). Medullary thyroid carcinoma occurred in no patient in the liraglutide group and 
in 1 in the placebo group. Calcitonin levels over time were similar in the two groups (data 
not shown).
Acute pancreatitis occurred in 18 patients in the liraglutide group and in 23 in the placebo 
group. The mean levels of serum amylase and lipase were higher in the liraglutide group 
than in the placebo group (Fig. S7 in the Supplementary Appendix). Acute gallstone disease 
was more common with liraglutide than with placebo (in 145 vs. 90 patients), including 
severe events (in 40 vs. 31). During the trial, fewer patients in the liraglutide group were 
treated with hypoglycemic medications (insulin, sulfonylurea, and glinides) than in the 
placebo group (Table S4 in the Supplementary Appendix). Severe hypoglycemia occurred in 
114 patients in the liraglutide group and in 153 in the placebo group (rate ratio, 0.69; 95% 
CI, 0.51 to 0.93). Similarly, the rate ratio for confirmed hypoglycemia (plasma glucose level, 
<56 mg per deciliter [3.1 mmol per liter]) was 0.80 (95% CI, 0.74 to 0.88). Additional 
details regarding severe hypoglycemia are provided in Table S6 in the Supplementary 
Appendix.
Adverse events leading to the permanent discontinuation of the trial regimen were more 
common with liraglutide than with placebo (Table 2). This result appears to have been driven 
by gastrointestinal disorders in the liraglutide group.
DISCUSSION
In the present trial, patients in the liraglutide group had a lower risk of the primary 
composite outcome — first occurrence of cardiovascular death, nonfatal myocardial 
infarction, or non-fatal stroke in the time-to-event analysis — and lower risks of death from 
cardiovascular causes, death from any cause, and microvascular events than did those in the 
placebo group. The number of patients who would need to be treated to prevent one event in 
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3 years was 66 in the analysis of the primary outcome and 98 in the analysis of death from 
any cause.10 There has been concern about the risk of hospitalization for heart failure with 
various agents that have been used to treat diabetes mellitus, including DPP-4 inhibitors.11 
In the present trial, there were fewer hospitalizations for heart failure among patients in the 
liraglutide group than among those in the placebo group, although the difference was not 
significant.
Sensitivity analyses suggested that our findings were robust to baseline adjustment and 
alternative censoring. Cardiovascular benefits were observed in the context of generally 
acceptable levels of cardiovascular risk-factor management at baseline and during the trial. 
There were fewer add-on therapies for diabetes medications, lipid-lowering medications, and 
diuretics in patients in the liraglutide group than in those in the placebo group. Subgroup 
analyses suggest a greater benefit of liraglutide with respect to the primary outcome in 
patients with an eGFR of less than 60 ml per minute per 1.73 m2 and possibly in patients 
with a history of cardiovascular disease. A sensitivity analysis of data for patients with an 
eGFR of less than 60 ml per minute per 1.73 m2 did not support a clinically meaningful 
interaction (Table S3 in the Supplementary Appendix).
The pattern of cardiovascular benefits that were associated with liraglutide in our trial 
appears to differ from that with the sodium–glucose cotransporter 2 inhibitor empagliflozin 
in the previously reported EMPA-REG OUTCOME trial.12 The time to benefit emerged 
earlier in that trial than in the present trial, and the heterogeneity of the direction and 
magnitude of the effects on the components of the primary composite outcome in that trial 
contrasts with the consistency of the effect in the present trial. Although these differences 
may reflect patient populations or chance, the observed benefits in that trial may be more 
closely linked to hemodynamic changes, whereas in the present trial, the observed benefits 
are perhaps related to the modified progression of atherosclerotic vascular disease.13
It should be noted that in the Evaluation of Lixisenatide in Acute Coronary Syndrome 
(ELIXA) trial,14 the GLP-1–receptor agonist lixisenatide, which is shorter-acting than and 
structurally dissimilar to liraglutide, did not show any cardiovascular benefit in patients with 
diabetes and a recent acute coronary syndrome. There are a number of other trials regarding 
cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which 
similar magnitude effects on glycemic control have been shown but without significant 
benefits with respect to rates of cardiovascular events or death.15–20 These include trials with 
insulin,16 thiazolidinediones,15,18 and DPP-4 inhibitors.17,19,20 Our trial had greater 
statistical power and included patients with a higher baseline glycated hemoglobin level than 
did most previous studies. However, no obvious single explanation in terms of either the 
study designs or the included populations is apparent to explain the divergent findings across 
this body of medical literature.
The prespecified primary microvascular outcome in our trial was a composite of 
nephropathy and retinopathy outcomes. The benefit with liraglutide was driven by lower 
rates of renal outcomes, such as new-onset persistent macro-albuminuria in particular. There 
was a higher rate of retinopathy events with liraglutide than with placebo, although the 
difference was not significant. With moderate differences in glycemic control between the 
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trial groups over a median 3.8 years of follow-up, the achievement of renal microvascular 
benefits is surprising. It is uncertain whether this finding relates to the direct effects of 
liraglutide on kidney function.21,22
More patients in the liraglutide group than in the placebo group permanently discontinued 
the trial regimen owing to adverse events (difference, 2.2 percentage points). There has been 
considerable interest in a potential association between the use of GLP-1–receptor agonists 
and pancreatitis and pancreatic cancer, although there is no consistent preclinical, 
pharmacovigilance, or epidemiologic evidence to date.23–25 Higher levels of lipase and 
amylase were observed in the liraglutide group, a finding that is similar to results in other 
studies.24 Blinded medications were to be stopped only in relation to confirmed pancreatitis 
as evaluated by the investigator. There were 1.5 episodes of pancreatitis per 1000 patient-
years of observation in both regimens combined, and there were numerically fewer acute or 
chronic pancreatitis events with liraglutide than with placebo. There were more episodes of 
gallstone disease with liraglutide, a finding that has been reported previously.26
An excess in adjudicated cancers of pancreatic origin was observed in the liraglutide group, 
although the finding was not significant; there were small overall numbers and no between-
group difference in the number of overall cancers. Among rodents receiving liraglutide, 
higher rates of thyroid C-cell tumors and hyperplasia have been observed than were 
observed among control animals.27 In the present trial, no episodes of C-cell hyperplasia or 
medullary thyroid carcinoma were observed in patients in the liraglutide group. Randomized 
trials of this type, despite their size, are not powered to determine the effect of drugs on 
cancer risk and can therefore neither confirm nor exclude such a possibility.
Many patients in each group were treated with sulfonylureas or insulin at baseline, but fewer 
patients in the liraglutide group than in the placebo group added insulin during the trial. 
There was a 31% lower rate of severe hypoglycemia and a 20% lower rate of the 
combination of severe and confirmed hypoglycemia (plasma glucose level, <56 mg per 
deciliter) in the liraglutide group than in the placebo group.
A limitation of our trial is that patients were followed for only 3.5 to 5.0 years, so the safety 
and efficacy data are restricted to that time period. Also, because our trial recruited a 
population of patients who were at high risk for cardiovascular events and who had a 
baseline glycated hemoglobin level of 7% or more, the observed benefits and risks may not 
apply to patients at lower risk. Furthermore, no adjustments were made for multiplicity of 
exploratory outcomes.
In conclusion, among patients with type 2 diabetes who were at high risk for cardiovascular 
events while they were taking standard therapy, those in the liraglutide group had lower rates 
of cardiovascular events and death from any cause than did those in the placebo group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Primary and Exploratory Outcomes
The primary composite outcome in the time-to-event analysis was the first occurrence of 
death from cardiovascular causes, nonfatal myocardial infarction, or non-fatal stroke. The 
cumulative incidences were estimated with the use of the Kaplan–Meier method, and the 
hazard ratios with the use of the Cox proportional-hazard regression model. The data 
analyses are truncated at 54 months, because less than 10% of the patients had an 
observation time beyond 54 months. The insets show the same data on an enlarged y axis.
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Figure 2. Primary Composite Outcomes in Various Demographic and Clinical Subgroups
Prespecified Cox proportional-hazard regression analyses were performed for subgroups of 
patients with respect to the primary outcome (first occurrence of death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfatal stroke). P values signify tests of 
homogeneity for between-group differences with no adjustment for multiple testing. The 
percentages of patients with a first primary outcome between the randomization date and the 
date of last follow-up are shown. Race and ethnic group were self-reported. There were 
missing data for the body-mass index (the weight in kilograms divided by the square of the 
height in meters) in 5 patients in the liraglutide group and 4 in the placebo group and for the 
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duration of diabetes in 11 patients in the liraglutide group and 8 in the placebo group. Renal 
function was assessed by means of the estimated glomerular filtration rate, as calculated by 
the Modification of Diet in Renal Disease equation. CVD denotes cardiovascular disease.
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Table 2
Selected Adverse Events Reported during the Trial.*
Event Liraglutide (N = 4668) Placebo (N = 4672) P Value
no. of patients (%)
Adverse event
 Any adverse event 2909 (62.3) 2839 (60.8) 0.12
 Serious adverse event 2320 (49.7) 2354 (50.4) 0.51
 Confirmed hypoglycemia† 2039 (43.7) 2130 (45.6) 0.06
Severe adverse event 1502 (32.2) 1533 (32.8) 0.51
 Severe hypoglycemia† 114 (2.4) 153 (3.3) 0.02
 Acute gallstone disease 145 (3.1) 90 (1.9) <0.001
  Cholelithiasis 68 (1.5) 50 (1.1) 0.09
  Acute cholecystitis 36 (0.8) 21 (0.4) 0.046
 Hypothyroidism 44 (0.9) 33 (0.7) 0.21
 Hyperthyroidism 13 (0.3) 8 (0.2) 0.27
 Diabetic foot ulcer 181 (3.9) 198 (4.2) 0.38
 Allergic reaction 59 (1.3) 44 (0.9) 0.14
 Injection-site reaction 32 (0.7) 12 (0.3) 0.002
Adverse event leading to permanent discontinuation of trial regimen
 Any adverse event 444 (9.5) 339 (7.3) <0.001
 Serious adverse event 192 (4.1) 245 (5.2) 0.01
 Severe adverse event 164 (3.5) 188 (4.0) 0.20
 Nausea 77 (1.6) 18 (0.4) <0.001
 Vomiting 31 (0.7) 2 (<0.1) <0.001
 Diarrhea 27 (0.6) 5 (0.1) <0.001
 Increased lipase level‡ 15 (0.3) 11 (0.2) 0.43
 Abdominal pain 11 (0.2) 3 (0.1) 0.03
 Decreased appetite 11 (0.2) 2 (<0.1) 0.01
 Abdominal discomfort 10 (0.2) 0 0.002
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Event Liraglutide (N = 4668) Placebo (N = 4672) P Value
no. of patients (%)
Pancreatitis or neoplasm§
 Acute pancreatitis 18 (0.4) 23 (0.5) 0.44
 Chronic pancreatitis 0 2 (<0.1) 0.16
 Any benign neoplasm 168 (3.6) 145 (3.1) 0.18
 Any malignant neoplasm 296 (6.3) 279 (6.0) 0.46
 Pancreatic carcinoma 13 (0.3) 5 (0.1) 0.06
 Medullary thyroid carcinoma 0 1 (<0.1) 0.32
*Serious adverse events and nonserious medical events of special interest were identified by search in the Medical Dictionary for Regulatory 
Activities, version 18.0. Permanent discontinuation of the treatment regimen was indicated by the investigator in the adverse-event form. P values 
were calculated by means of Pearson’s chi-square test.
†Confirmed hypoglycemia was defined a plasma glucose level of less than 56 mg per deciliter (3.1 mmol per liter). Severe hypoglycemia was 
defined as hypoglycemia for which the patient required assistance from a third party.
‡
Increased lipase levels were those that were reported by the investigator as adverse events.
§
Events of pancreatitis and neoplasms were adjudicated by the event-adjudication committee. This committee interpreted neoplastic growth as 
clonal disorders that grow in an autonomous manner. The abnormality of clonal disorder may not always have been identified nor could 
autonomous growth always be determined, but both were considered to be fundamental aspects of neoplastic growth.
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